HC Wainwright keeps $4.00/share target on enGene Therapeutics
HC Wainwright & Co. maintained its price target at $4.00 per share for enGene Therapeutics, according to ratings actions cited.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.